CSIMarket


Ligand Pharmaceuticals Incorporated  (LGND)
Other Ticker:  
 

Ligand Pharmaceuticals Incorporated

LGND's Fundamental analysis








Ligand Pharmaceuticals Incorporated's sales fell by -50.27 % in III. Quarter 2023 from the same quarter a year ago. Ranking at No. 3718

Major Pharmaceutical Preparations industry recorded deterioration of revenues by -4.74 %

Ligand Pharmaceuticals Incorporated faced net loss in contrast to the net income a year ago in III. Quarter 2023

More on LGND's Growth


Ligand Pharmaceuticals Incorporated
current PE on trailing twelve month basis is below Major Pharmaceutical Preparations industry average.

Ligand Pharmaceuticals Incorporated PEG ratio is at -0.49 Company is currently trading with Price to Cash flow multiple of 75.78 in trailing twelve-month period.
Company
82.21
PE TTM   
Industry
268.41
PE TTM    
Company's Price to Sales ratio is at 9.16.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.71.


More on LGND's Valuation
 
 Total Debt (Millions $) -
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Revenue/Employee (TTM) $ 874,215
 Net Income/Employee (TTM) $ -
 Receivable Turnover (TTM) 4.22
 Tangible Book Value (Per Share $) 14.34

Ligand Pharmaceuticals Incorporated
current PE on trailing twelve month basis is below Major Pharmaceutical Preparations industry average.

Ligand Pharmaceuticals Incorporated PEG ratio is at -0.49 Company is currently trading with Price to Cash flow multiple of 75.78 in trailing twelve-month period.
Company
82.21
PE TTM   
Industry
268.41
PE TTM    
Company's Price to Sales ratio is at 9.16.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.71.

Ligand Pharmaceuticals Incorporated Price to Book Ratio is at 1.79 lower than Indusry Avg. of 1284.34. and higher than S&P 500 Avg. of 0.01

More on LGND's Valuation

  Market Capitalization (Millions $) 1,193
  Shares Outstanding (Millions) 17
  Employees 149
  Revenues (TTM) (Millions $) 130
  Net Income (TTM) (Millions $) 16
  Cash Flow (TTM) (Millions $) 16
  Capital Exp. (TTM) (Millions $) -5
  Total Debt (Millions $) -
  Dividend TTM ($) 0 $
  Dividend Yield TTM (%) -
  Revenue/Employee (TTM) $ 874,215
  Net Income/Employee(TTM) $ -
  Receivable Turnover Ratio (TTM) 4.22
  Tangible Book Value (Per Share $) 14.34

  Market Capitalization (Millions $) 1,193
  Shares Outstanding (Millions) 17
  Employees 149
  Revenues (TTM) (Millions $) 130
  Net Income (TTM) (Millions $) 16
  Cash Flow (TTM) (Millions $) 16
  Capital Exp. (TTM) (Millions $) -5


    LGND's Profitability Comparisons
Ligand Pharmaceuticals Incorporated achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in III. Quarter 2023 to 9.36 %.







  Ratio
   Capital Ratio (MRQ) 16.15
  Total Debt to Equity (MRQ) -
  Tangible Leverage Ratio (MRQ) 0.41
  Asset Turnover Ratio (TTM) 0.17
  Inventory Turnover Ratio (TTM) 1.33



Ligand Pharmaceuticals Incorporated achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in III. Quarter 2023 to 9.36 %.



More on LGND's Key Ratios





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com